Taura L Barr

US Patent:

20130189243, Jul 25, 2013

Filed:

Feb 22, 2011

Appl. No.:

13/580571

Inventors:

Taura L. Barr - Waynesburg PA, US
Maria Del Mar Matarin - Kent, GB
Steven Jay Warach - West Lake Hills TX, US
Andrew Barry Singleton - Poolesville MD, US
Yvette P. Conley - North Huntingdon PA, US

International Classification:

C12Q 1/68
A61B 6/00
A61B 5/055
G01N 33/68
A61B 5/00

US Classification:

424 9464, 436501, 435 792, 506 9, 435 612, 435 611, 506 18, 506 16, 435 71, 5303898, 536 2431, 530300, 600407, 600410, 378 4

Abstract:

The present invention provides methods and compositions for the diagnosis of acute ischemic stroke. The invention further provides methods and compositions for distinguishing acute ischemic stroke from other forms of stroke and TIAs and “stroke mimic” events. Moreover, methods and compositions are provided to facilitate the treatment of acute ischemic stroke patients.

US Patent:

20140221235, Aug 7, 2014

Filed:

Jan 29, 2014

Appl. No.:

14/167059

Inventors:

Taura L. Barr - Waynesburg PA, US

Assignee:

WEST VIRGINIA UNIVERSITY - Morgantown WV

International Classification:

C12Q 1/68

US Classification:

506 9, 536 2431, 5303892, 506 18, 506 16, 5303891

Abstract:

A method of determining the time of stroke symptom onset is provided including obtaining a biological sample from an individual; contacting the biological sample with a detection composition comprising at least one expression mediator of a LY96, ARG1, CA4, and a TLR expression mediators, or a combination of these expression mediators, wherein at least one of the expression mediators is associated with an acute phase response of ischemic stroke, for forming a detectable response; and correlating the detectable response with a time of onset of one or more stroke symptoms. A composition is provided having a nucleic acid probe, an antibody, or a purified biomarker that is specific for at least one of a LY96, ARG1, CA4, and TLR expression mediators, or a combination of these expression mediators.